141 related articles for article (PubMed ID: 28881658)
21. Vorinostat and bortezomib synergistically cause ubiquitinated protein accumulation in prostate cancer cells.
Sato A; Asano T; Ito K; Asano T
J Urol; 2012 Dec; 188(6):2410-8. PubMed ID: 23088964
[TBL] [Abstract][Full Text] [Related]
22. Identification of a novel synergistic induction of cell death by Smac mimetic and HDAC inhibitors in acute myeloid leukemia cells.
Steinwascher S; Nugues AL; Schoeneberger H; Fulda S
Cancer Lett; 2015 Sep; 366(1):32-43. PubMed ID: 26028172
[TBL] [Abstract][Full Text] [Related]
23. Interplay of RUNX1/MTG8 and DNA methyltransferase 1 in acute myeloid leukemia.
Liu S; Shen T; Huynh L; Klisovic MI; Rush LJ; Ford JL; Yu J; Becknell B; Li Y; Liu C; Vukosavljevic T; Whitman SP; Chang KS; Byrd JC; Perrotti D; Plass C; Marcucci G
Cancer Res; 2005 Feb; 65(4):1277-84. PubMed ID: 15735013
[TBL] [Abstract][Full Text] [Related]
24. Genetic blockade of insulin-like growth factor-1 receptor via recombinant adenovirus in lung cancer can be enhanced by the histone deacetylase inhibitor, vorinostat.
Park MY; Kim DR; Eo EY; Lim HJ; Park JS; Cho YJ; Yoon HI; Lee JH; Lee CT
J Gene Med; 2013; 15(3-4):115-22. PubMed ID: 23413016
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with DNA methyltransferase inhibitors in hematologic malignancies.
Gore SD
Nat Clin Pract Oncol; 2005 Dec; 2 Suppl 1():S30-5. PubMed ID: 16341238
[TBL] [Abstract][Full Text] [Related]
26. Preclinical studies of vorinostat (suberoylanilide hydroxamic acid) combined with cytosine arabinoside and etoposide for treatment of acute leukemias.
Shiozawa K; Nakanishi T; Tan M; Fang HB; Wang WC; Edelman MJ; Carlton D; Gojo I; Sausville EA; Ross DD
Clin Cancer Res; 2009 Mar; 15(5):1698-707. PubMed ID: 19223502
[TBL] [Abstract][Full Text] [Related]
27. Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia.
Cashen AF; Schiller GJ; O'Donnell MR; DiPersio JF
J Clin Oncol; 2010 Feb; 28(4):556-61. PubMed ID: 20026803
[TBL] [Abstract][Full Text] [Related]
28. Chidamide plus decitabine synergistically induces apoptosis of acute myeloid leukemia cells by upregulating
Li Q; Huang JC; Liao DY; Wu Y
Am J Transl Res; 2020; 12(7):3461-3475. PubMed ID: 32774712
[TBL] [Abstract][Full Text] [Related]
29. Deguelin, a selective silencer of the NPM1 mutant, potentiates apoptosis and induces differentiation in AML cells carrying the NPM1 mutation.
Yi S; Wen L; He J; Wang Y; Zhao F; Zhao J; Zhao Z; Cui G; Chen Y
Ann Hematol; 2015 Feb; 94(2):201-10. PubMed ID: 25242579
[TBL] [Abstract][Full Text] [Related]
30. Phase I study of decitabine alone or in combination with valproic acid in acute myeloid leukemia.
Blum W; Klisovic RB; Hackanson B; Liu Z; Liu S; Devine H; Vukosavljevic T; Huynh L; Lozanski G; Kefauver C; Plass C; Devine SM; Heerema NA; Murgo A; Chan KK; Grever MR; Byrd JC; Marcucci G
J Clin Oncol; 2007 Sep; 25(25):3884-91. PubMed ID: 17679729
[TBL] [Abstract][Full Text] [Related]
31. Adipocyte-mediated epigenomic instability in human T-ALL cells is cytotoxic and phenocopied by epigenetic-modifying drugs.
Lee M; Geitgey DK; Hamilton JAG; Boss JM; Scharer CD; Spangle JM; Haynes KA; Henry CJ
Front Cell Dev Biol; 2022; 10():909557. PubMed ID: 36060800
[TBL] [Abstract][Full Text] [Related]
32. Urinary retention after use of decitabine in acute myeloid leukemia: case report.
Nunes VRH; E Pimentel IS; Kerbauy MN; Feres CCP; Nascimento JZMD; Ribeiro AAF; Santos AIDD; Wroclawski ML; Teixeira LLC; Hamerschlak N
Hematol Transfus Cell Ther; 2023; 45(1):110-112. PubMed ID: 34257059
[No Abstract] [Full Text] [Related]
33. Tyrosine kinase inhibition increases the cell surface localization of FLT3-ITD and enhances FLT3-directed immunotherapy of acute myeloid leukemia.
Reiter K; Polzer H; Krupka C; Maiser A; Vick B; Rothenberg-Thurley M; Metzeler KH; Dörfel D; Salih HR; Jung G; Nößner E; Jeremias I; Hiddemann W; Leonhardt H; Spiekermann K; Subklewe M; Greif PA
Leukemia; 2018 Feb; 32(2):313-322. PubMed ID: 28895560
[TBL] [Abstract][Full Text] [Related]
34. The mTOR inhibitor everolimus in combination with azacitidine in patients with relapsed/refractory acute myeloid leukemia: a phase Ib/II study.
Tan P; Tiong IS; Fleming S; Pomilio G; Cummings N; Droogleever M; McManus J; Schwarer A; Catalano J; Patil S; Avery S; Spencer A; Wei A
Oncotarget; 2017 Aug; 8(32):52269-52280. PubMed ID: 28881728
[TBL] [Abstract][Full Text] [Related]
35. Acute myeloid leukemia with mutated nucleophosmin 1: an immunogenic acute myeloid leukemia subtype and potential candidate for immune checkpoint inhibition.
Greiner J; Hofmann S; Schmitt M; Götz M; Wiesneth M; Schrezenmeier H; Bunjes D; Döhner H; Bullinger L
Haematologica; 2017 Dec; 102(12):e499-e501. PubMed ID: 28935849
[No Abstract] [Full Text] [Related]
36. Emerging therapies for acute myeloid leukemia: translating biology into the clinic.
Kavanagh S; Murphy T; Law A; Yehudai D; Ho JM; Chan S; Schimmer AD
JCI Insight; 2017 Sep; 2(18):. PubMed ID: 28931762
[TBL] [Abstract][Full Text] [Related]
37. Synergistic suppression of t(8;21)-positive leukemia cell growth by combining oridonin and MAPK1/ERK2 inhibitors.
Spirin P; Lebedev T; Orlova N; Morozov A; Poymenova N; Dmitriev SE; Buzdin A; Stocking C; Kovalchuk O; Prassolov V
Oncotarget; 2017 Aug; 8(34):56991-57002. PubMed ID: 28915648
[TBL] [Abstract][Full Text] [Related]
38. Identification of precision treatment strategies for relapsed/refractory multiple myeloma by functional drug sensitivity testing.
Majumder MM; Silvennoinen R; Anttila P; Tamborero D; Eldfors S; Yadav B; Karjalainen R; Kuusanmäki H; Lievonen J; Parsons A; Suvela M; Jantunen E; Porkka K; Heckman CA
Oncotarget; 2017 Aug; 8(34):56338-56350. PubMed ID: 28915594
[TBL] [Abstract][Full Text] [Related]
39. Extracellular S100A9 Protein in Bone Marrow Supports Multiple Myeloma Survival by Stimulating Angiogenesis and Cytokine Secretion.
De Veirman K; De Beule N; Maes K; Menu E; De Bruyne E; De Raeve H; Fostier K; Moreaux J; Kassambara A; Hose D; Heusschen R; Eriksson H; Vanderkerken K; Van Valckenborgh E
Cancer Immunol Res; 2017 Oct; 5(10):839-846. PubMed ID: 28903971
[TBL] [Abstract][Full Text] [Related]
40. Genetic Predisposition to Multiple Myeloma at 5q15 Is Mediated by an ELL2 Enhancer Polymorphism.
Li N; Johnson DC; Weinhold N; Kimber S; Dobbins SE; Mitchell JS; Kinnersley B; Sud A; Law PJ; Orlando G; Scales M; Wardell CP; Försti A; Hoang PH; Went M; Holroyd A; Hariri F; Pastinen T; Meissner T; Goldschmidt H; Hemminki K; Morgan GJ; Kaiser M; Houlston RS
Cell Rep; 2017 Sep; 20(11):2556-2564. PubMed ID: 28903037
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
